Please login to the form below

European prostate cancer treatment is changing - what are the opportunities for marketers?

Consultant Jeremy Poland examines some of the key dynamics in prostate cancer multi-disciplinary teams across Europe and how the recent trends impact the opportunities available to healthcare marketers.
In this article, Consultant Jeremy Poland examines some of the key dynamics in prostate cancer multi-disciplinary teams across Europe. He will cover what we mean by multidisciplinary team, who the key stakeholders are in prostate cancer, the critical trend we are currently seeing, and the opportunities this provides to healthcare marketers operating in the area.


What is a multi-disciplinary team?

Expressed very simply, a multi-disciplinary team (MDT) represents a number of different medical functions that are involved in the management of patient care. The term MDT is itself a very British expression – across Europe the model may be referred to in a number of ways (e.g. Clinical Tumour Board, Academic Tumour Board, Multi-Specialty Practice etc.), and may be implemented with varying degrees of formality. 

In oncology, the existence of MDTs is actually nothing new. In fact, we can look back 50 years or more to the US and can find a cousin of the existing model in the form of educational tumour boards. And until relatively recently, that is exactly what they were – educational. It was the in the late 90s and early 00s when the UK, driven by public and political pressure to improve the consistency of patient care, reformed the provision of cancer services to include regular multidisciplinary meetings as a way to formally implement the MDT model. A key goal of this transformation was to improve communication between medical functions whilst also ensuring decision making was evidence based and improving continuity of care and outcomes for patients.

Such was the success of this approach in the UK, many other European countries began to follow suit and adopt the MDT model for cancer care in their region.


Key stakeholders in prostate cancer MDTs

Of course healthcare systems across the EU have their idiosyncrasies, and as such, those stakeholders involved in the management of prostate cancer (and indeed their degree of involvement) varies by region. Broadly speaking, however, the key members of an MDT will include a urologist, medical oncologist, radiation oncologist, radiologist, pathologist, pharmacist, and clinical nurse specialist – who often fulfils the role of MDT coordinator or key worker. These functions will make up the group, panel or board depending on the preference of the region. 



Download the full article from Blue Latitude Health

5th August 2016

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health (UK)
140 Aldersgate Street
London
EC1A 4HY
United Kingdom

Latest content on this profile

In the precision medicine era, the line between products and services is blurred
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?
Blue Latitude Health
Understanding COVID-19 and varying responses across the globe
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
Blue Latitude Health
Top 5 tips for a multi-indication product launch
Senior Associate Consultant Sana Rahim and Senior Consultant Victoria Clark explain the lessons the team has learned from launching six different indications of an oncology product in an accelerated timeframe.
Blue Latitude Health
If our patients are diverse, why are clinical trials so white?
Despite facing worse health outcomes, minority populations are often left out of clinical trials and miss the opportunity to participate in life-saving research. Associate Consultant Ling Song explores this issue and calls for the pharmaceutical industry to change its approach.
Blue Latitude Health
Engaging physicians during COVID-19
COVID-19 has drastically changed the lives of healthcare professionals. They are emotionally and physically drained and under huge amounts of pressure. They also need pharma’s help. Senior Consultant Pany Koizi outlines five principles for engaging with physicians during the pandemic.
Blue Latitude Health
Fishawack Health adds market access and commercial strategy consultancy Skysis as part of its bold growth plans
Fishawack Health, the global healthcare communications agency, announces the acquisition of Skysis, a boutique consulting firm providing integrated market access and commercial strategy solutions based in the US.
Blue Latitude Health